222 related articles for article (PubMed ID: 15623849)
1. Arthritis medicines and cardiovascular events--"house of coxibs".
Topol EJ
JAMA; 2005 Jan; 293(3):366-8. PubMed ID: 15623849
[No Abstract] [Full Text] [Related]
2. Raising the safety bar--the FDA's coxib meeting.
Okie S
N Engl J Med; 2005 Mar; 352(13):1283-5. PubMed ID: 15800221
[No Abstract] [Full Text] [Related]
3. Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
Couzin J
Science; 2005 Feb; 307(5713):1183-5. PubMed ID: 15731414
[No Abstract] [Full Text] [Related]
4. Coxibs and cardiovascular risk.
Allen MJ; McLean-Veysey P; Fleming I
CMAJ; 2005 Oct; 173(8):853. PubMed ID: 16217098
[No Abstract] [Full Text] [Related]
5. COX-2 inhibitors--a lesson in unexpected problems.
Drazen JM
N Engl J Med; 2005 Mar; 352(11):1131-2. PubMed ID: 15713947
[No Abstract] [Full Text] [Related]
6. Coxibs and cardiovascular disease.
Fitzgerald GA
N Engl J Med; 2004 Oct; 351(17):1709-11. PubMed ID: 15470192
[No Abstract] [Full Text] [Related]
7. Does celecoxib use increase the risk of cardiovascular events?
Oviedo JA; Schroy PC
Gastroenterology; 2005 Oct; 129(4):1348-50. PubMed ID: 16230088
[No Abstract] [Full Text] [Related]
8. Celecoxib approved as NSAID with some concessions on class warning.
Miller JL
Am J Health Syst Pharm; 1999 Mar; 56(5):403. PubMed ID: 10096694
[No Abstract] [Full Text] [Related]
9. New, long-term insights from the Adenoma Prevention with Celecoxib Trial on a promising but troubled class of drugs.
Dubois RN
Cancer Prev Res (Phila); 2009 Apr; 2(4):285-7. PubMed ID: 19336723
[No Abstract] [Full Text] [Related]
10. The pain game.
Wadman M
Nature; 2007 Jul; 448(7152):400-1. PubMed ID: 17653159
[No Abstract] [Full Text] [Related]
11. COX-2 inhibitors--lessons in drug safety.
Psaty BM; Furberg CD
N Engl J Med; 2005 Mar; 352(11):1133-5. PubMed ID: 15713946
[No Abstract] [Full Text] [Related]
12. Balancing the risks and benefits of celecoxib.
Caldwell B; Beasley R; Weatherall M; Metcalfe S
Am J Med; 2007 Jun; 120(6):e17. PubMed ID: 17524734
[No Abstract] [Full Text] [Related]
13. The coxibs, selective inhibitors of cyclooxygenase-2.
FitzGerald GA; Patrono C
N Engl J Med; 2001 Aug; 345(6):433-42. PubMed ID: 11496855
[No Abstract] [Full Text] [Related]
14. Risks and benefits of celecoxib to prevent recurrent adenomas.
Psaty BM; Potter JD
N Engl J Med; 2006 Aug; 355(9):950-2. PubMed ID: 16943408
[No Abstract] [Full Text] [Related]
15. COX-2 inhibitors and cardiovascular toxicity: a class effect?
Laible B
S D J Med; 2005 Mar; 58(3):93-4. PubMed ID: 15794479
[No Abstract] [Full Text] [Related]
16. Tailoring arthritis therapy in the wake of the NSAID crisis.
Olsen NJ
N Engl J Med; 2005 Jun; 352(25):2578-80. PubMed ID: 15972863
[No Abstract] [Full Text] [Related]
17. COX-2 selective drugs and cardiovascular risks: same data but discrepant conclusions?
Bannwarth B
Expert Opin Drug Saf; 2006 Jan; 5(1):1-2; author reply 1-2. PubMed ID: 16370948
[No Abstract] [Full Text] [Related]
18. How celecoxib could be safer, how valdecoxib might have been.
Cohen JS
Ann Pharmacother; 2005 Sep; 39(9):1542-5. PubMed ID: 16076909
[TBL] [Abstract][Full Text] [Related]
19. Celecoxib shown effective in preventing colon polyps.
Nelson NJ
J Natl Cancer Inst; 2006 May; 98(10):665-7. PubMed ID: 16705118
[No Abstract] [Full Text] [Related]
20. The COX-2 inhibitors--an update.
Furberg CD
Am Heart J; 2006 Aug; 152(2):197-9. PubMed ID: 16875896
[No Abstract] [Full Text] [Related]
[Next] [New Search]